MedTrace Logo

PET Adapted Treatment of Patients With Limited Stage DLBCL and no Risk Factors

NCT05078840 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2024-01-09

No results posted yet for this study

Summary

Prospective, multicenter, phase IV study, of real-life evidence destined to evaluate the feasibility and efficacy of performing a treatment adapted to PET-CT in patients with stage I and II DLBCL, without poor prognostic factors.

Conditions

  • Lymphoma, Non-Hodgkin's, Adult

Interventions

OTHER

Evaluation of first line treatment in patients with stage I and II LBCL

Evaluation of first line treatment in patients with stage I and II LBCL, without poor prognostic factors with treatment adapted to PET-CT after 3 R-CHOP

Sponsors & Collaborators

  • Grupo Argentino de Tratamiento de la Leucemia Aguda

    lead OTHER

Principal Investigators

  • Amalia Cerutti, Dr. · Grupo Argentino de Tratamiento de la Leucemia Aguda

  • Astrid Pavlovsky, Dr. · Grupo Argentino de Tratamiento de la Leucemia Aguda

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2024-06-01
Completion
2025-06-01

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05078840 on ClinicalTrials.gov